David Olmos

9PUBLICATIONS
106CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 02, 2026
Germline CDK12 variants in aggressive prostate cancer.

|Oct 02, 2024
SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer.

Antonio J Montero-Hidalgo, Juan M Jiménez-Vacas, Enrique Gómez-Gómez

|Sep 16, 2024
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.

Fred Saad, Egils Vjaters, Neal Shore

|Nov 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.

Joaquin Mateo, Johann S de Bono, Karim Fizazi

|Mar 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.

Kim N Chi, Dana Rathkopf, Matthew R Smith

|Nov 04, 2022
IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer.

Lorelei A Mucci, Jacob Vinson, Theresa Gold

Pageof 2

Frequent Collaborators

6 joint publications

Kim N Chi

3 joint publications

Joaquin Mateo

3 joint publications

Shahneen Sandhu

3 joint publications

Johann S de Bono